Radiation Oncologist, main focus on prostate and lung. Basketball lover. #radonc
Padua, Veneto
Joined September 2019
- Tweets26
- Following124
- Followers148
- Likes572
Matteo Sepulcri retweeted
Does nodal irradiation explain the negative results of concurrent Chemo-ICI-RT observed in Pacific-2 and Checkmate 73L? Better a 'perioperative like' strategy Chemo-ICI ->ChemoRT->ICI?
Novel scenarios for unresectable stage III NSCLC discussed by @AntonioNuccio01 and @mat_sepu
Matteo Sepulcri retweeted
Fully published @JTOonline our individual patient data meta-analysis on EFS in pts w/ resectable NSCLC treated w/ neoadj Chemo-IO.
An effort led by @dmarinelli93 @AntonioNuccio01 @filippog92 on behalf of a young Italian multidisciplinary oncology group
bit.ly/3YO1iCU
1/4
Matteo Sepulcri retweeted
Individual patient data meta-analysis @JTOonline of neoadjuvant or perioperative trials in resectable NSCLC shows pCR or MPR with neoadjuvant chemo-immunotherapy associated with improved EFS, similar with or without adjuvant immunotherapy component.
jto.org/article/S1556-0864(2…
Matteo Sepulcri retweeted
Sala gremita a Castelfranco Veneto durante i lavori del 2° giorno di 'Advanced Uro-Oncology'.
Un evento dedicato ad oncologi, urologi e radioterapisti con Resp. Scientifici Dott. Marco Maruzzo, Prof. Angelo Porreca, Dott. Matteo Sepulcri. @therealmarcodoc @PorrecaAngelo @mat_sepu
Matteo Sepulcri retweeted
Grande successo per la 2° edizione del congresso ‘Advanced Uro-Oncology’ a Castelfranco Veneto.
Responsabili Scientifici: Dott. Marco Maruzzo, Prof. Angelo Porreca, Dott. Matteo Sepulcri. @therealmarcodoc @PorrecaAngelo @mat_sepu
#Oncologia #Urologia #Radioterapia
Matteo Sepulcri retweeted
A partire da domani 18 e 19 aprile a Castelfranco Veneto (TV)
Advanced Uro-Oncology Days
Responsabili Scientifici Dott.ri Marco Maruzzo, Angelo Porreca, Matteo Sepulcri. @therealmarcodoc @mat_sepu
Programma ed iscrizioni: overgroup.eu/evento/advanced…
Matteo Sepulcri retweeted
LUNG-ART trial out in @TheLancetOncol: bit.ly/3J3ZNH1
Postoperative #radiotherapy in IIIA pN2 NSCLC pts
- no increase in DFS (HR 0.86, p=0.18) or OS
- increase in late G3/4 cardiopulm tox
Negative results but huge work by Dr Cécile Le Péchoux from @GustaveRoussy #lcsm
Metabolic features can predict response to radical RT for prostate cancer! #PCSM
Happy to share our latest work with many thanks to all colleagues and friends @lauraevangelis9 @MarcoFusella
doi.org/10.1016/j.ctro.2021.…
Matteo Sepulcri retweeted
So proud to present our Guidelines for Radiotherapy of Bladder Cancer
➡️ GETUG-AFU Recommendations for planning and delivery of radical radiotherapy for ... sciencedirect.com/science/ar… – at Bordeaux, France
Matteo Sepulcri retweeted
Updated meta-analysis of PORT for completely resected Masaoka stage II/III Thymoma
☑️ n=4746 pts
⬆️ OS with HR=0.68
⬆️ Similar beneficial effect in stage II and III
#radonc
jto.org/article/S1556-0864(2…
Matteo Sepulcri retweeted
Prospective single arm phase II trial of SBRT for oligometastatic NSCLC
➡️ SBRT was delivered after 2-4 mo systemic Tx
➡️ About 40% were treated with TKI
➡️ Sig. improved PFS for pts with complete metabolic response (median 54 mo)
➡️ No G4 tox
#radonc
lungcancerjournal.info/artic…
Matteo Sepulcri retweeted
Our recently completed meta-analysis comparing conventional RT to SRS for management of spinal metastases just published in the Green Journal! @EricLehrer @NicholasZaorsky @DanTrifMD sciencedirect.com/science/ar…
Matteo Sepulcri retweeted
Red Journal: Article in Press!
Patterns of Recurrence and Modes of Progression Following Metastasis Directed Therapy in Oligometastatic Castration Sensitive Prostate Cancer
Deek et al.
doi.org/10.1016/j.ijrobp.202….
Matteo Sepulcri retweeted
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel mCRPC Identifies an Excess of Long-term Survivors
#VisualAbstract
@AlbertoBossial @HouedeNadine @neerajaiims
buff.ly/3awcpWw
Matteo Sepulcri retweeted
ESTRO-ACROP guidelines for Target Volume Definition in #SCLC:
-Consider clusters of smaller LNs with SAD < 1 cm.
-Consider ipsi SCV if level 2 or 3a involved.
-CTV = GTV + 5 mm, particularly in CC direction for nodes.
-No adaptive nodal cone-down. #radonc
pubmed.ncbi.nlm.nih.gov/3267…
Matteo Sepulcri retweeted
Our paper on the effect of radiotherapy-related lymphopenia on overall survival in patients with lung cancer utilizing image-based data mining is now published online in @JTOonline
doi.org/10.1016/j.jtho.2020.…
@AzadehAbravan @RT_physics @MCRCnews
Matteo Sepulcri retweeted
Meta-analysis of radiotherapy for prostate cancer: 8 weeks (conventional fractionation) vs 5 weeks (hypofractionation) vs ~1 week (ultra-hypofractionation) of treatment
@EricLehrer @AmarUKishan @jamesbyu @DanTrifMD @TimShowalter1 @OncologyAdvance
#pcsm #RadOnc
Matteo Sepulcri retweeted
ASCO abstract: Randomised phase II trial suggests pts with LD SCLC might benefit from higher dose of thoracic RT (60Gy in 40Fx BID) compared to standard dose (45Gy in 30Fx BID); median OS 42mo vs 23mo (HR 0.63) #radonc meetinglibrary.asco.org/reco…
Matteo Sepulcri retweeted
Protocol for the phase III RCT SABR-COMET-3 published online at BMC Cancer, doi.org/10.1186/s12885-020-0… which we are re-opening in BC after a short COVID break, with international sites opening soon!
